COVLA Trademark

Trademark Overview


On Monday, December 16, 2019, a trademark application was filed for COVLA with the United States Patent and Trademark Office. The USPTO has given the COVLA trademark a serial number of 88728523. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 11, 2023. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The COVLA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
covla

General Information


Serial Number88728523
Word MarkCOVLA
Filing DateMonday, December 16, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 11, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 21, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of neurological disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, December 19, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Monday, September 11, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, September 11, 2023ABANDONMENT - NO USE STATEMENT FILED
Friday, February 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 16, 2023SOU EXTENSION 5 GRANTED
Wednesday, February 1, 2023SOU EXTENSION 5 FILED
Thursday, February 16, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, February 1, 2023SOU TEAS EXTENSION RECEIVED
Friday, August 12, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 10, 2022SOU EXTENSION 4 GRANTED
Wednesday, August 10, 2022SOU EXTENSION 4 FILED
Wednesday, August 10, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, February 9, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 7, 2022SOU EXTENSION 3 GRANTED
Monday, February 7, 2022SOU EXTENSION 3 FILED
Monday, February 7, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, November 10, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, November 10, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, November 10, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, November 10, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, August 6, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 4, 2021SOU EXTENSION 2 GRANTED
Wednesday, August 4, 2021SOU EXTENSION 2 FILED
Wednesday, August 4, 2021SOU TEAS EXTENSION RECEIVED
Saturday, February 13, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 11, 2021SOU EXTENSION 1 GRANTED
Thursday, February 11, 2021SOU EXTENSION 1 FILED
Thursday, February 11, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, August 11, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, July 1, 2020EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Wednesday, May 20, 2020EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, April 21, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 21, 2020PUBLISHED FOR OPPOSITION
Wednesday, April 1, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, March 16, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, March 16, 2020ASSIGNED TO EXAMINER
Thursday, December 19, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 19, 2019NEW APPLICATION ENTERED